ARAMINE Drug Patent Profile
✉ Email this page to a colleague
When do Aramine patents expire, and what generic alternatives are available?
Aramine is a drug marketed by Merck and is included in one NDA.
The generic ingredient in ARAMINE is metaraminol bitartrate. There is one drug master file entry for this compound. Additional details are available on the metaraminol bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aramine
A generic version of ARAMINE was approved as metaraminol bitartrate by SLAYBACK PHARMA LLC on August 24th, 2021.
Summary for ARAMINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 52 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ARAMINE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ARAMINE
US Patents and Regulatory Information for ARAMINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | ARAMINE | metaraminol bitartrate | INJECTABLE;INJECTION | 009509-002 | Dec 22, 1987 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |